IP Library Granted Patent US 11,759,450
Granted Patent B2
US 11,759,450 · App. 16/967,188 · Granted Sep 19, 2023

Substituted benzothiophene analogs as selective estrogen receptor degraders

Inventors: Gregory R. Thatcher (Chicago, IL); Rui Xiong (Chicago, IL); Jiong Zhao (Chicago, IL); Yunlong Lu (Chicago, IL); Lauren Gutgesell (Chicago, IL); Carlo Ivan Rosales (Chicago, IL); Yangfeng Li (Chicago, IL)
Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
A61K31/397A61K31/138A61K31/167A61K31/277A61K31/4025A61K31/4196A61K31/4535A61K31/565A61K31/566A61K31/573A61K38/09A61K39/3955A61K45/06C07D409/12C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,759,450
App. No.
16/967,188
Granted
Sep 19, 2023
Kind
B2
Abstract

In one aspect, the disclosure relates to relates to substituted benzothiophene analogs which are useful as selective degraders of estrogen receptor, methods of making same, pharmaceutical compositions comprising same, and methods of treating one or more clinical conditions associated with estrogen receptor, such as a cancer, including breast cancer, or osteoporosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Claims (20)

1. A compound having a structure represented by a formula:

wherein m is selected from 0 and 1;

wherein p is selected from 0, 1, and 2;

wherein q is selected from 0, 1, and 2;

wherein each of Z 1 and Z 2 is independently selected from —CH— or —N—; provided Z 1 and Z 2 are not simultaneously —CH— or —N—; and provided when Z 1 is —CH— and m is 1, that p and q are not both 0;

wherein Z 10 is selected from —O— or —NH—;

wherein Z 11 is, when present, —CH 2 CH 2 —;

wherein Z 40 is —(CH 2 ) n —;

wherein each of R 10a and R 10b are independently selected from hydrogen, deuterium, halogen, and C1-C3 methyl;

wherein R is C1-C6 alkyl, C1-C6 haloalkyl, halogen, or hydroxy; and

wherein n is selected from 0, 1, 2, and 3;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein Z 10 is —O—.

3. The compound of claim 1 , wherein Z 40 is selected from —(CH 2 )— and —(CH 2 ) 3 —.

4. The compound of claim 1 wherein —Z 1 — is N and Z 2 is —CH—.

5. The compound of claim 1 wherein —Z 1 — is —CH— and Z 2 is —N—.

6. The compound of claim 1 , having a structure represented by a formula:

7. The compound of claim 1 , having a structure represented by a formula:

8. The compound of claim 1 , having a structure represented by a formula:

9. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Continuity (3)
Provisional Application 62657046 · Apr 13, 2018
Provisional Application 62626785 · Feb 6, 2018
Related Publication 20220062230A1 · Mar 3, 2022